MA41265B1 - Compositions pour administration de médicaments iléo-jéjunal. - Google Patents
Compositions pour administration de médicaments iléo-jéjunal.Info
- Publication number
- MA41265B1 MA41265B1 MA41265A MA41265A MA41265B1 MA 41265 B1 MA41265 B1 MA 41265B1 MA 41265 A MA41265 A MA 41265A MA 41265 A MA41265 A MA 41265A MA 41265 B1 MA41265 B1 MA 41265B1
- Authority
- MA
- Morocco
- Prior art keywords
- ileo
- jejunal
- drugs
- administration
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 210000000813 small intestine Anatomy 0.000 abstract 2
- 229940124291 BTK inhibitor Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 210000003405 ileum Anatomy 0.000 abstract 1
- 230000002427 irreversible effect Effects 0.000 abstract 1
- 210000001630 jejunum Anatomy 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096812P | 2014-12-24 | 2014-12-24 | |
| PCT/US2015/000515 WO2016105582A1 (en) | 2014-12-24 | 2015-12-23 | Compositions for ileo-jejunal drug delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41265A MA41265A (fr) | 2017-10-31 |
| MA41265B1 true MA41265B1 (fr) | 2023-05-31 |
Family
ID=55361929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41265A MA41265B1 (fr) | 2014-12-24 | 2015-12-23 | Compositions pour administration de médicaments iléo-jéjunal. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20180193274A1 (enExample) |
| EP (1) | EP3236943B1 (enExample) |
| JP (1) | JP6687248B2 (enExample) |
| DK (1) | DK3236943T3 (enExample) |
| ES (1) | ES2942642T3 (enExample) |
| FI (1) | FI3236943T3 (enExample) |
| HR (1) | HRP20230305T1 (enExample) |
| HU (1) | HUE061809T2 (enExample) |
| LT (1) | LT3236943T (enExample) |
| MA (1) | MA41265B1 (enExample) |
| PL (1) | PL3236943T3 (enExample) |
| PT (1) | PT3236943T (enExample) |
| RS (1) | RS64139B1 (enExample) |
| SI (1) | SI3236943T1 (enExample) |
| WO (1) | WO2016105582A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2892900T3 (pl) | 2012-09-10 | 2018-02-28 | Principia Biopharma Inc. | Związki pyrazolopirymidonowe jako inhibitory kinazy |
| SMT201700160T1 (it) | 2013-04-25 | 2017-05-08 | Beigene Ltd | Composti eterociclici fusi come inibitori di protein chinasi |
| ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| CA2939186C (en) | 2014-02-21 | 2023-03-07 | Principia Biopharma Inc. | Salts and solid form of a btk inhibitor |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| US10485797B2 (en) | 2014-12-18 | 2019-11-26 | Principia Biopharma Inc. | Treatment of pemphigus |
| MA42242A (fr) | 2015-06-24 | 2018-05-02 | Principia Biopharma Inc | Inhibiteurs de la tyrosine kinase |
| SG11201809751XA (en) | 2016-05-26 | 2018-12-28 | Zeno Royalties & Milestones Llc | Egfr inhibitor compounds |
| MX390619B (es) | 2016-06-29 | 2025-03-21 | Principia Biopharma Inc | Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| WO2018033853A2 (en) | 2016-08-16 | 2018-02-22 | Beigene, Ltd. | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| PT3500299T (pt) | 2016-08-19 | 2024-02-21 | Beigene Switzerland Gmbh | Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro |
| CN106588937B (zh) * | 2017-01-16 | 2018-09-21 | 东莞市真兴贝特医药技术有限公司 | 咪唑并吡嗪类化合物及其制备方法和应用 |
| CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
| TW202515616A (zh) | 2017-06-26 | 2025-04-16 | 英屬開曼群島商百濟神州有限公司 | 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途 |
| CN110997677A (zh) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | 具有改进的双重选择性的Btk抑制剂 |
| CN114478544B (zh) * | 2017-09-28 | 2023-06-16 | 上海海雁医药科技有限公司 | 4,6,7-三取代1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| US11576917B2 (en) | 2018-01-20 | 2023-02-14 | Natco Pharma Limited | Pharmaceutical compositions comprising Ibrutinib |
| KR102328682B1 (ko) | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| MX2021003064A (es) * | 2018-09-18 | 2021-05-27 | Beijing Innocare Pharma Tech Co Ltd | Formas cristalinas de 6-(1-acriloilpiperidin-4-il)-2-(4-fenoxifeni l)nicotinamida. |
| MX2021004965A (es) * | 2018-11-06 | 2021-06-15 | Beijing Innocare Pharma Tech Co Ltd | Dispersion solida amorfa que comprende 6-(1-acriloilpiperidin-4-il )-2-(4-fenoxifenil)nicotinamida. |
| WO2020102304A1 (en) * | 2018-11-13 | 2020-05-22 | Rain Therapeutics Inc. | Combination of a kinase inhibitor and an electrolyte, compositions and methods comprising the same |
| PL3666262T3 (pl) * | 2018-12-10 | 2022-02-28 | Aphaia Ip Ag | Farmaceutyczne doustne postaci dawkowania do leczenia zaburzeń metabolicznych i powiązanych chorób poprzez zorganizowane uwalnianie enterokin |
| CN109851725A (zh) * | 2018-12-29 | 2019-06-07 | 华南理工大学 | 纳米纤维素-聚丙烯酰胺-明胶复合水凝胶、其制备方法及应用 |
| WO2020249001A1 (zh) | 2019-06-10 | 2020-12-17 | 百济神州瑞士有限责任公司 | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 |
| CN114787150A (zh) | 2019-08-15 | 2022-07-22 | 黑钻治疗公司 | 炔基喹唑啉化合物 |
| MX2022004427A (es) | 2019-10-14 | 2022-07-12 | Principia Biopharma Inc | Metodos para el tratamiento de la trombocitopenia inmunitaria mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-feno xi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-m etil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo. |
| WO2021080375A1 (en) * | 2019-10-24 | 2021-04-29 | Hanmi Pharm. Co., Ltd. | A pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same |
| KR20220130184A (ko) | 2020-01-22 | 2022-09-26 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1H-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 결정질 형태 |
| TW202235083A (zh) * | 2020-11-02 | 2022-09-16 | 美商黑鑽醫療公司 | 使用經炔取代之喹唑啉衍生物類以治療癌症之方法 |
| WO2022260667A1 (en) * | 2021-06-10 | 2022-12-15 | Hikma Pharmaceuticals Usa Inc. | Oral dosage forms of ibrutinib |
| CN113855695B (zh) * | 2021-11-01 | 2023-06-06 | 上海理工大学 | 一种结肠释药口服复方药物组合物及其制备方法 |
| CN114181159B (zh) * | 2021-12-28 | 2024-02-20 | 南通大学 | 含2,4,5-三取代嘧啶酰肼衍生物及其制备方法与应用 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| CN116473923B (zh) * | 2023-05-29 | 2024-05-14 | 杭州剂泰医药科技有限责任公司 | 一种奈拉替尼固体分散体组合物及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2771010A4 (en) * | 2011-10-19 | 2015-04-01 | Pharmacyclics Inc | USE OF BRUTON TYROSINE KINASE (BTK) INHIBITORS |
| US20160045503A1 (en) * | 2012-06-18 | 2016-02-18 | Principia Biopharma Inc. | Formulations containing reversible covalent compounds |
| WO2014004707A1 (en) | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| PL2892900T3 (pl) * | 2012-09-10 | 2018-02-28 | Principia Biopharma Inc. | Związki pyrazolopirymidonowe jako inhibitory kinazy |
| SG10201705437SA (en) * | 2013-01-05 | 2017-07-28 | Elcelyx Therapeutics Inc | Delayed-release composition comprising biguanide |
-
2015
- 2015-12-23 WO PCT/US2015/000515 patent/WO2016105582A1/en not_active Ceased
- 2015-12-23 US US15/539,100 patent/US20180193274A1/en not_active Abandoned
- 2015-12-23 MA MA41265A patent/MA41265B1/fr unknown
- 2015-12-23 EP EP15834774.0A patent/EP3236943B1/en active Active
- 2015-12-23 SI SI201531939T patent/SI3236943T1/sl unknown
- 2015-12-23 JP JP2017533932A patent/JP6687248B2/ja active Active
- 2015-12-23 LT LTEPPCT/US2015/000515T patent/LT3236943T/lt unknown
- 2015-12-23 HU HUE15834774A patent/HUE061809T2/hu unknown
- 2015-12-23 ES ES15834774T patent/ES2942642T3/es active Active
- 2015-12-23 PT PT158347740T patent/PT3236943T/pt unknown
- 2015-12-23 DK DK15834774.0T patent/DK3236943T3/da active
- 2015-12-23 RS RS20230281A patent/RS64139B1/sr unknown
- 2015-12-23 PL PL15834774.0T patent/PL3236943T3/pl unknown
- 2015-12-23 HR HRP20230305TT patent/HRP20230305T1/hr unknown
- 2015-12-23 FI FIEP15834774.0T patent/FI3236943T3/fi active
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20230305T1 (hr) | 2023-05-26 |
| JP2018500353A (ja) | 2018-01-11 |
| HUE061809T2 (hu) | 2023-08-28 |
| US20180193274A1 (en) | 2018-07-12 |
| JP6687248B2 (ja) | 2020-04-22 |
| EP3236943B1 (en) | 2023-01-25 |
| MA41265A (fr) | 2017-10-31 |
| ES2942642T3 (es) | 2023-06-05 |
| SI3236943T1 (sl) | 2023-06-30 |
| LT3236943T (lt) | 2023-04-11 |
| PT3236943T (pt) | 2023-04-20 |
| RS64139B1 (sr) | 2023-05-31 |
| WO2016105582A1 (en) | 2016-06-30 |
| FI3236943T3 (fi) | 2023-04-27 |
| DK3236943T3 (da) | 2023-04-11 |
| PL3236943T3 (pl) | 2023-05-29 |
| EP3236943A1 (en) | 2017-11-01 |
| HK1245071A1 (en) | 2018-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41265B1 (fr) | Compositions pour administration de médicaments iléo-jéjunal. | |
| IL264065A (en) | Oral gastroretentive formulations and uses thes thereof | |
| MX375752B (es) | Inhibidores de tirosina quinasa de bruton. | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| CL2017003320A1 (es) | Formulaciones farmacéuticas que contienen tenofovir y emtricitabina | |
| MA43187A (fr) | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| NZ733135A (en) | Fused pyrimidine compounds for the treatment of hiv | |
| TN2016000094A1 (en) | Inhibitors of bruton's tyrosine kinase. | |
| DK3576788T3 (da) | Farmaceutisk sammensætning med lavt ph, der omfatter t-celle-engagerende antistofkontruktioner | |
| EA202090683A3 (ru) | Способы и композиции для лечения рака | |
| MX2017016802A (es) | Formulaciones farmaceuticas. | |
| JO3570B1 (ar) | صيغ للإعطاء بالفم من ديفيرازيروكس | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| GEP20196961B (en) | 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139 | |
| DK3634468T5 (da) | Fast sammensætning til oral indgivelse | |
| MX389178B (es) | Formulacion de proporcion fija de insulina glargina/lixisenatida. | |
| MA49947A (fr) | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes | |
| HUE062579T2 (hu) | Baktériumokat tartalmazó orális gyógyszerészeti formuláció | |
| EP3318282A4 (en) | AGGREGATE COMPOSITION CARRIER AND COMPOSITION THEREOF | |
| MX387731B (es) | Composiciones farmacéuticas orales de mesalazina. | |
| PH12016501686A1 (en) | Pharmaceutical compositions of sitagliptin | |
| HUE059630T2 (hu) | Nátrium-fenil-butirátot tartalmazó, kellemes ízû készítmények és alkalmazásaik | |
| JO3456B1 (ar) | فيروتيوكسيتين بيروجلوتامات | |
| JOP20170115B1 (ar) | مشتقات بيريدينيل، تركيبات صيدلية منها واستخداماتها كمثبطات aoc3 |